Emerge Diagnostics Raises $1.85 Million in Capital

Wednesday, June 29, 2016 | 1

Emerge Diagnostics, a company that sells systems for assessing soft-tissue injuries, raised $1.85 million in financing this month, according to a U.S. Securities and Exchange Commission filing.

It’s the third round of financing for the company, which has raised $3.75 million since its launch in 2012, MedCity News reported.

Chief Executive Officer Robert Thompson told MedCity News that the funds would be used for hiring at least four full-time sales people, adding to the current sales staff of two.

The company, based in Carlsbad, California, markets an electrodiagnostic functional assessment test, or EFA, to identify the location, extent, nature and age of soft tissue injuries, according to its website. Emerge’s EFA combines electromyography, a measurement of electrical activity in a muscle, with range-of-motion, functional assessment, pinch-strength and grip-strength testing.

Soft-tissue injuries, such as strains of the back, neck, shoulder, show up often in workers’ compensation claims.

Through a program called EFA Soft Tissue Management, Emerge offers to conduct baseline testing of workers’ muscle condition, which can be compared to measurements after a claim is filed claiming a soft-tissue injury. That may help determine if the tissue damage was pre-existing, according to the company.

Thompson said the company’s sales team will target states between Texas and North and South Dakota, an area where demand has been strongest.